BMO Capital lowered its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $160.00 (from $165.00) while maintaining an Outperform rating.Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE